New drug targets rare gene mutations in Hard-to-Treat cancers

NCT ID NCT06716138

Recruiting now Disease control Sponsor: Avistone Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Mar 24, 2026 · Last updated May 25, 2026 · Updated 12 times

Summary

This early-stage study tests a new drug called ANS03 in people with advanced solid tumors that have specific gene changes (ROS1 or NTRK). The main goals are to check the drug's safety and see if it can shrink tumors. About 96 adults will take part, and the drug is given alone without other treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS HARBORING A ROS1 OR NTRK ALTERATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10022, United States
Research Site
RECRUITING

Fuzhou, Fujian, China
Research Site
RECRUITING

Guangzhou, Guangdong, China
Research Site
RECRUITING

Shanghai, Shanghai Municipality, China
Research Site
RECRUITING

Chengdu, Sichuan, China

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED OR METASTATIC SOLID TUMORS HARBORING A ROS1 OR NTRK ALTERATION